Achieve Life Sciences Inc ACHV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACHV is a good fit for your portfolio.
News
-
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
-
Milestone Pharmaceuticals Refreshes Board of Directors
-
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
-
Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes
-
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
-
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
-
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
-
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
Trading Information
- Previous Close Price
- $4.89
- Day Range
- $4.80–5.00
- 52-Week Range
- $3.03–5.98
- Bid/Ask
- $4.70 / $5.20
- Market Cap
- $169.13 Mil
- Volume/Avg
- 62,321 / 243,916
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 22
Comparables
Valuation
|
Metric
|
ACHV
|
HLVX
|
PCVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.41 | 0.39 | 4.61 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ACHV
HLVX
PCVX
Financial Strength
|
Metric
|
ACHV
|
HLVX
|
PCVX
|
|---|---|---|---|
Quick Ratio | 3.23 | 10.92 | 17.25 |
Current Ratio | 3.29 | 10.92 | 17.42 |
Interest Coverage | −8.17 | −56.32 | — |
Quick Ratio
ACHV
HLVX
PCVX
Profitability
|
Metric
|
ACHV
|
HLVX
|
PCVX
|
|---|---|---|---|
Return on Assets (Normalized) | −70.65% | −34.73% | −20.32% |
Return on Equity (Normalized) | −185.69% | −44.29% | −21.78% |
Return on Invested Capital (Normalized) | −72.68% | −39.50% | −26.68% |
Return on Assets
ACHV
HLVX
PCVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Xknsjqxh | Qycl | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qzmbdbkl | Dthvxqr | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wzjdbqb | Vrxtlx | $118.7 Bil | |||
| Moderna Inc
MRNA
| Qhnnzbvyj | Pqhz | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bywljrj | Gsjmkgy | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Qpxnygty | Zygc | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Fqcxnnr | Zvjy | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cpbnjfbn | Cndvmt | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Brhgqqzf | Pcymq | $15.0 Bil | |||
| Incyte Corp
INCY
| Ffjynmkl | Bymvsd | $13.5 Bil |